Literature DB >> 23055201

Activation of β-catenin signaling is critical for doxorubicin-induced epithelial-mesenchymal transition in BGC-823 gastric cancer cell line.

Rongfei Han1, Jie Xiong, Ruijing Xiao, Ehtisham Altaf, Jin Wang, Yanping Liu, Hui Xu, Qianshan Ding, Qiuping Zhang.   

Abstract

The epithelial-mesenchymal transition (EMT) is a fundamental process governing morphogenesis in multicellular organisms and has recently been implicated in promoting carcinoma invasion and metastasis. Besides their therapeutic effects, accumulating evidences suggest that chemotherapeutic agents also induced EMT and enhanced the malignancy of treated cancer cells; however, the mechanism(s) still remains unclear. Here, we investigated the role of β-catenin signaling in doxorubicin (Dox)-induced EMT in human gastric cancer cell line BGC-823. We found that the transient treatment of Dox induced EMT and enhanced the in vitro migration ability of cancer cells. We also found that β-catenin signaling was activated upon Dox treatment. Inhibition of β-catenin by indomethacin (Indo) or siRNA suppressed Dox-induced EMT and decreased cancer cell migration ability. Our results showed that β-catenin signaling was critical to Dox-induced EMT. Indo and other β-catenin inhibitors may have a potential implication in prevention of gastric cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055201     DOI: 10.1007/s13277-012-0548-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

Authors:  Jing Yang; Robert A Weinberg
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 4.  A perspective on cancer cell metastasis.

Authors:  Christine L Chaffer; Robert A Weinberg
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

5.  Epithelial mesenchymal transition and lung cancer.

Authors:  Dakai Xiao; Jianxing He
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

6.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

7.  Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs.

Authors:  Desheng Lu; Howard B Cottam; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

Review 8.  Epithelial-mesenchymal transitions: twist in development and metastasis.

Authors:  Yibin Kang; Joan Massagué
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

9.  Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.

Authors:  Abhik Bandyopadhyay; Long Wang; Joseph Agyin; Yuping Tang; Shu Lin; I-Tien Yeh; Keya De; Lu-Zhe Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

10.  Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy.

Authors:  Kensuke Yamauchi; Meng Yang; Katsuhiro Hayashi; Ping Jiang; Norio Yamamoto; Hiroyuki Tsuchiya; Katsuro Tomita; Abdool R Moossa; Michael Bouvet; Robert M Hoffman
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

View more
  8 in total

1.  CNTN-1 Upregulation Induced by Low-Dose Cisplatin Promotes Malignant Progression of Lung Adenocarcinoma Cells via Activation of Epithelial-Mesenchymal Transition.

Authors:  Ruijie Zhang; Shengjin Li; Jian Lan; Changyi Li; Xianzhi Du; Weijie Dong; Qian Yu; Daoxin Wang
Journal:  Front Genet       Date:  2022-05-27       Impact factor: 4.772

2.  ZNF143 enhances metastasis of gastric cancer by promoting the process of EMT through PI3K/AKT signaling pathway.

Authors:  Song Wei; Linjun Wang; Lei Zhang; Bowen Li; Zheng Li; Qun Zhang; Jiwei Wang; Liang Chen; Guangli Sun; Qing Li; Hao Xu; Diancai Zhang; Zekuan Xu
Journal:  Tumour Biol       Date:  2016-07-23

Review 3.  Epithelial-mesenchymal transition in gastric cancer.

Authors:  Lei Huang; Ruo-Lin Wu; A-Man Xu
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

4.  Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.

Authors:  Jiahui Xu; Deying Liu; Huilin Niu; Guifang Zhu; Yangwei Xu; Danli Ye; Jian Li; Qingling Zhang
Journal:  J Exp Clin Cancer Res       Date:  2017-01-26

5.  Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/β-catenin signaling pathway in breast cancer.

Authors:  Xiaoxia Jin; Yingze Wei; Yushan Liu; Xiaoyun Lu; Fei Ding; Jiatai Wang; Shuyun Yang
Journal:  Cancer Med       Date:  2019-01-29       Impact factor: 4.452

6.  The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells.

Authors:  Ana Flórido; Nuno Saraiva; Sara Cerqueira; Nuno Almeida; Maddy Parsons; Ines Batinic-Haberle; Joana P Miranda; João G Costa; Guia Carrara; Matilde Castro; Nuno G Oliveira; Ana S Fernandes
Journal:  Redox Biol       Date:  2018-10-25       Impact factor: 11.799

7.  DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway.

Authors:  Mashael S Al-Mutairi; Hany O Habashy
Journal:  Molecules       Date:  2022-09-20       Impact factor: 4.927

8.  DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.

Authors:  Xing Kang; Minhuan Li; Hao Zhu; Xiaofeng Lu; Ji Miao; Shangce Du; Xuefeng Xia; Wenxian Guan
Journal:  Oncotarget       Date:  2017-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.